← All trials
NCT05422222
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2022
- Primary completion
- Jun 30, 2030
- Completion date
- Jun 30, 2030
- First posted
- Jun 16, 2022
- Last posted
- Aug 31, 2022
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- VertexLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.